Actively Recruiting
Phase 1 Study of Zavegepant Nasal Spray to Assess Safety and How the Body Processes It in Children Aged 6 to Under 12 with Migraine
Led by Pfizer · Updated on 2026-03-18
16
Participants Needed
13
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying the safety and how the body processes the medicine called Zavegepant PF-07930207 in children aged 6 to less than 12 years who have a history of migraine. The study focuses on understanding how the body changes and removes this medicine after taking it. Participants must have had migraines for at least 6 months and weigh more than 15 kilograms. All children in the study will receive a single dose of Zavegepant as a nasal spray, with the dose depending on their weight. Each participant will get one spray into one nostril. This is an open-label study, meaning everyone receives the study medicine, and the effects of different doses will be observed. The study lasts up to 10 weeks. During the study period, participants will attend 3 clinic visits and have 2 follow-up phone calls. Researchers will monitor the medicines concentration in the blood at specific times after dosing. They will also track any side effects and changes in vital signs, lab results, and mental health. The main outcomes involve measuring how much and how quickly the medicine appears in the blood.
CONDITIONS
Brief Title
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
